Updated:
Worldwide Clinical Trials Holdings
Worldwide Clinical Trials is a top-rated, full-service global CRO. We provide 30+ years of clinical expertise to benefit your study. Learn more about us here.
Worldwide Clinical Trials Holdings
Worldwide Clinical Trials is a top-rated, full-service global CRO. We provide 30+ years of clinical expertise to benefit your study. Learn more about us here.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
United States
Corporate office
United States
Principals
Alistair Macdonald
Chief Executive Officer
Michael Murphy
Chief Medical and Scientific Officer
Lona Sheeran
Senior Vice President, Clinical Operations Early Phase
Sector focus
Frequently asked questions
Who runs investment decisions at Worldwide Clinical Trials Holdings?
Investment decisions are led by CEO Alistair Macdonald, appointed in 2026 (per firm press release, 2026). Dr. Michael Murphy serves as Chief Medical and Scientific Officer, overseeing therapeutic strategy. The firm does not disclose a formal investment committee or external GP relationships.
How does Worldwide Clinical Trials source proprietary deal flow?
The firm originates business through clinical trial service contracts with pharmaceutical and biotechnology companies. Its deal flow is driven by therapeutic expertise and relationships with drug developers, rather than through traditional investment sourcing channels like fund commitments or co-investments.
Is Worldwide Clinical Trials structured as a family office or a venture firm?
Worldwide Clinical Trials Holdings is a contract research organization (CRO), not a family office or venture firm. It generates revenue through clinical trial services rather than capital deployment. Ownership and wealth origin are not publicly disclosed.
What investment stages does Worldwide Clinical Trials typically target?
The firm supports clinical development across all phases — from early-phase through late-stage trials. Its services are tailored to therapeutic areas such as oncology, neuroscience, rare disease, and cell and gene therapy. Specific stage preferences or fund structures are not publicly available.
Does Worldwide Clinical Trials maintain philanthropic structures?
No philanthropic structures or foundations are disclosed on the firm's public website. The company focuses exclusively on contract research services. Any related vehicles or affiliations are not publicly documented.
Where does the underlying wealth come from at Worldwide Clinical Trials?
Wealth origin for Worldwide Clinical Trials Holdings is not publicly disclosed. The firm's ownership structure and ultimate beneficial owner are not identified in available sources.
What is Worldwide Clinical Trials' known posture on co-investments alongside external GPs?
Worldwide Clinical Trials does not appear to participate in co-investments alongside external GPs. Its business model is service-oriented, providing clinical trial management rather than direct investment. No co-investment activity has been publicly reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: